Blood-based PD-L1 analysis (on soluble PD-L1, exosomal PD-L1 and PD-L1 in circulating tumor cells) also showed potential to predict treatment efficacy in NSCLC both before and after treatment with ICI. This evidence concerns the gene CD274 and neoplasm.